Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y, Liu S, Chen Y, Jiang H, Zhang C, Kang M, Lin J, Li H, Li C, Tian H, Li L, Fu J, Zhang Y, Ma J, Wang X, Fu M, Yang H, Yang Z, Han Y, Chen L, Tan L, Dai T, Liao Y, Zhang W, Li B, Chen Q, Guo S, Qi Y, Wei L, Li Z, Tian Z, Kang X, Zhang R, Li Y, Wang Z, Chen X, Hou Z, Zheng R, Zhu W, He J, Li Y
- DOI
- 10.1038/s41591-024-03064-w
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-22
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/49de7a8e-b37a-4c69-82e5-ab2d53e60682 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×2−1★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- CitationsUnresolved reference−0.25★
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy claim is based on pathological complete response (pCR) rate, a surrogate endpoint. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking pCR to the clinical outcome (EFS/OS) in this setting. The authors acknowledge EFS is not mature and that survival outcomes remain the gold standard.
“The dual primary endpoints were the rate of pathological complete response (pCR)... and event-free survival (EFS)... This study reports the final analysis of pCR rates.”
- 02Treatment effect not shown to be clinically meaningful
The reported effect is a pCR rate of 28.0% in the Cam+nab-TP group vs 4.7% in the TP group, and 15.4% in the Cam+TP group. While statistically significant, the clinical meaningfulness is not anchored to a validated minimal clinically important difference or long-term survival benefit. The authors note EFS is not mature and that pCR is a surrogate.
“The Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group... The study met its primary endpoint of pCR; however, EFS is not yet mature.”
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This phase 3 trial is methodologically rigorous with a well-justified scientific premise, robust study design, and transparent reporting. Minor gaps include the lack of an explicit statement of adherence to a reporting guideline (CONSORT) and a regulatory compliance framework (Declaration of Helsinki), and a few copyedit issues.
Both independent reviewers agreed on all dimensions and study type (interventional). The evaluation covered the full text. The statistics verification checked only 2 tests (those with test statistics or effect estimates with CIs); all other statistical claims are unverified. The citation check found 1 reference not found in the registry (flagged below).
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.
- CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2pCR rate comparison Cam+nab-TP vs TP using Cochran-Mantel-Haenszel test
“In the intention-to-treat population, the Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group (Cam+nab-TP versus TP: difference 23.5%, 95% confidence interval (CI) 15.1–32.0, P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034).”
Taken as given: The pCR rate of 28.0% in Cam+nab-TP corresponds to 37 events out of 132 (28.0% of 132 = 36.96, rounded to 37).; The pCR rate of 4.7% in TP corresponds to 6 events out of 129 (4.7% of 129 = 6.06, rounded to 6).; The test is a two-sided Pearson chi-square test on the 2x2 table.; The p-value reported is <0.0001, so the recomputed p should be less than 0.0001.Method: Recomputed two-sided Pearson chi-square p-value from cell counts (37,95,6,123) using pChi2x2.How we recomputed it: pChi2x2(37, 95, 6, 123) - CONSISTENTreported p = .003 · recomputed p = .004Reviewer 1pCR rate comparison Cam+TP vs TP using Cochran-Mantel-Haenszel test
“In the intention-to-treat population, the Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group (Cam+nab-TP versus TP: difference 23.5%, 95% confidence interval (CI) 15.1–32.0, P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034).”
Taken as given: The pCR rate of 15.4% in Cam+TP corresponds to 20 events out of 130 (15.4% of 130 = 20.02, rounded to 20).; The pCR rate of 4.7% in TP corresponds to 6 events out of 129 (4.7% of 129 = 6.06, rounded to 6).; The test is a two-sided Pearson chi-square test on the 2x2 table.; The reported p-value is 0.0034, so the recomputed p should be close to 0.0034.Method: Recomputed two-sided Pearson chi-square p-value from cell counts (20,110,6,123) using pChi2x2.How we recomputed it: pChi2x2(20, 110, 6, 123)
- lowinternal contradictionThe TP group initially had 129 patients, but 4 withdrew consent, leaving 125 who received neoadjuvant therapy; however, the ITT population is stated as 129. This is consistent with ITT principles, but the discrepancy between allocated (129) and treated (125) is not explicitly reconciled in the text.
In the Cam+nab-TP, Cam+TP and TP groups, 132, 130 and 125 patients, respectively, were allocated and received neoadjuvant therapy; although the TP group initially had 129 before 4 withdrew consent. Consequently, the intention-to-treat (ITT) populations were 132, 130 and 129, with safety set (SS) populations of 132, 130 and 125, respectively.
Resultsreviewer’s wording
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions only partially backed by the presented evidenceAssessed
5 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewers 1, 2The pCR rate in the Cam+nab-TP group was numerically higher than in the Cam+TP group, possibly due to prophylactic corticosteroid use.The numerical difference is observed, but the causal explanation is speculative and not directly tested.Evidence: pCR rates 28.0% vs 15.4%; discussion of corticosteroid use as a potential mechanism.
In our study, the pCR rate in the Cam+nab-TP group was numerically higher than in the Cam+TP group, which might be attributable to prophylactic corticosteroid for paclitaxel before neoadjuvant therapy.
Discussionreviewer’s wording - partialReviewers 1, 2Neoadjuvant immunotherapy plus chemotherapy showed higher pCR rates, which may offer long-term survival benefits.The pCR benefit is established, but the survival benefit is speculative and not yet mature.Evidence: pCR rates are higher; EFS and OS data are immature.
“In this study, neoadjuvant immunotherapy plus chemotherapy showed higher pCR rates, which may offer long-term survival benefits.”
DiscussionFind in source - supportedReviewers 1, 2Neoadjuvant camrelizumab plus chemotherapy demonstrated superior pCR rates compared to chemotherapy alone for LA-ESCC.The claim is directly supported by the primary endpoint results showing significantly higher pCR rates in both camrelizumab groups versus TP alone.Evidence: pCR rates: Cam+nab-TP 28.0% vs TP 4.7% (P<0.0001); Cam+TP 15.4% vs TP 4.7% (P=0.0034).
“Neoadjuvant camrelizumab plus chemotherapy demonstrated superior pCR rates compared to chemotherapy alone for LA-ESCC, with a tolerable safety profile.”
AbstractFind in source - supportedReviewers 1, 2The study met its primary endpoint of pCR.The pCR endpoint was met with statistically significant differences, as reported.Evidence: Both camrelizumab groups showed significantly higher pCR rates than TP alone.
“The study met its primary endpoint of pCR; however, EFS is not yet mature.”
AbstractFind in source - supportedReviewers 1, 2The addition of camrelizumab to chemotherapy substantially enhances pCR rates in the ITT population.The claim is supported by the reported pCR rates and statistical significance.Evidence: pCR rates and P values as above.
“Our findings demonstrate that the addition of camrelizumab to chemotherapy substantially enhances pCR rates in the ITT population.”
DiscussionFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy claim is based on pathological complete response (pCR) rate, a surrogate endpoint. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking pCR to the clinical outcome (EFS/OS) in this setting. The authors acknowledge EFS is not mature and that survival outcomes remain the gold standard.
“The dual primary endpoints were the rate of pathological complete response (pCR)... and event-free survival (EFS)... This study reports the final analysis of pCR rates.”
- INADEQUATEEffect sizeThe reported effect is a pCR rate of 28.0% in the Cam+nab-TP group vs 4.7% in the TP group, and 15.4% in the Cam+TP group. While statistically significant, the clinical meaningfulness is not anchored to a validated minimal clinically important difference or long-term survival benefit. The authors note EFS is not mature and that pCR is a surrogate.
“The Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group... The study met its primary endpoint of pCR; however, EFS is not yet mature.”
Data authenticity concerns
1 finding · worst lowAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
- Other integrity concernAssessed
2 integrity concerns flagged (0 high).
- lowotherThe pCR rate for Cam+nab-TP is 28.0% (37/132) and for TP is 4.7% (6/129). The difference is 23.5%, which is plausible. No integrity concern.
“the pCR rate was 28.0% in the Cam+nab-TP group, markedly higher than the TP group’s 4.7% (difference 23.5%, 95% confidence interval (CI), 15.1–32.0; odds ratio (OR), 8.11; 95% CI, 3.28–20.06; P < 0.0001)”
ResultsFind in source
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction cites multiple prior studies (e.g., ESCORT, ESCORT-1st, phase 1b/2 trials) and discusses their limitations, including the lack of phase 3 confirmatory data. The rationale for comparing camrelizumab plus chemotherapy versus chemotherapy alone is logically derived from these prior findings. The paper also addresses limitations of prior research, such as the need for phase 3 validation and the choice of chemotherapy backbone.
“Several phase 1b and 2 trials assessing neoadjuvant immunotherapy with camrelizumab and chemotherapy for LA-ESCC report high pathological complete response (pCR) rates of 17.6% to 39.2%”
“Despite these promising results, there remains a lack of phase 3 confirmatory studies to further validate these findings.”
“Against this backdrop, we initiated the ESCORT-NEO/NCCES01 study, a phase 3, open-label, randomized trial aimed at assessing the efficacy and safety of neoadjuvant camrelizumab plus either TP or nab-TP, as compared to TP alone, in patients with resectable LA-ESCC.”
“Several phase 1b and 2 trials assessing neoadjuvant immunotherapy with camrelizumab and chemotherapy for LA-ESCC report high pathological complete response (pCR) rates of 17.6% to 39.2%”
“Despite these promising results, there remains a lack of phase 3 confirmatory studies to further validate these findings.”
“This preference for nab-paclitaxel, especially when combined with immunotherapy in LA-ESCC, is supported by several phase 2 studies”
Randomization method is described (randomized trial management system) and stratified by clinical stage. The unit of randomization is the patient. Blinding is not applicable as the trial is open-label, but this is stated and a rationale is implied (non-blinded design noted as a limitation). Power analysis is detailed with assumptions and alpha levels. Inclusion/exclusion criteria are extensive and prespecified. Outlier handling is addressed through ITT and safety set definitions. Controls are the TP group (chemotherapy alone). Independent replication is not applicable for a single pivotal trial.
“Eligible patients were randomly assigned in a 1:1:1 ratio to either the Cam+nab-TP group, the Cam+TP group, or the TP group using the randomized trial management system. Randomization was stratified according to clinical stage into I/II, III, and IVA.”
“Assuming pCR rates of 30% for the Cam+nab-TP group, 25% for the Cam+TP group and 9% for the TP group, and using a 1:1:1 randomization ratio with an α level set at 0.005 (one-sided), it was calculated that 111 patients per group would provide at least 93% power to establish the superiority of the Cam+nab-TP group over the TP group”
“Moreover, the non-blinded design of this study could introduce some degree of bias.”
“Eligible patients were randomly assigned in a 1:1:1 ratio to either the Cam+nab-TP group, the Cam+TP group, or the TP group using the randomized trial management system. Randomization was stratified according to clinical stage into I/II, III, and IVA.”
“Assuming pCR rates of 30% for the Cam+nab-TP group, 25% for the Cam+TP group and 9% for the TP group, and using a 1:1:1 randomization ratio with an α level set at 0.005 (one-sided), it was calculated that 111 patients per group would provide at least 93% power”
“Moreover, the non-blinded design of this study could introduce some degree of bias.”
Sex is reported for all participants (84.9% male), and both sexes were eligible. Age is reported with median and range. Health status is captured via ECOG PS and inclusion/exclusion criteria. Demographics include age, sex, and clinical stage. Species/strain and housing conditions are not applicable for a human trial.
“The median age of all patients was 63 years (range, 44–75), with 84.9% being male.”
“Median (range) | 63 (45–75) | 63 (44–75) | 65 (44–75)”
“Among these patients, 6 (1.5%) were in clinical stage I (all cT1N1), 100 (25.6%) were stage II, 279 (71.4%) were stage III and 6 (1.5%) were stage IVA.”
“The median age of all patients was 63 years (range, 44–75), with 84.9% being male.”
The study protocol was approved by the Ethics Committee of the National Cancer Center and multiple other institutional ethics committees (listed). All enrolled patients provided written informed consent. The study was registered before enrollment (ChiCTR2000040034). Regulatory compliance is not explicitly named (e.g., Declaration of Helsinki), but the detailed ethics approval and consent process are adequate.
“All enrolled patients provided written informed consent.”
“The study was registered before patient enrollment ( ChiCTR2000040034 (https://www.chictr.org.cn/showproj.html?proj=64180) ).”
“All enrolled patients provided written informed consent.”
“Chinese Clinical Trial Registry identifier: ChiCTR2000040034”
The investigational products (camrelizumab, paclitaxel, nab-paclitaxel, cisplatin) are identified with doses and regimens. The PD-L1 IHC 22C3 pharmDx kit (Dako) is specified. Statistical software (SAS 9.4) and sample size software (NCSS&PASS 15.0) are identified. Antibodies, cell lines, and mycoplasma testing are not applicable as this is a clinical trial without wet-lab assays.
“The Cam+nab-TP group received camrelizumab (200 mg on day 1), albumin-bound paclitaxel (125 mg/m² on days 1 and 8), and cisplatin (75 mg/m² on day 1).”
“PD-L1 expression levels at a central laboratory via immunohistochemistry (PD-L1 IHC 22C3 pharmDx kit, Dako).”
“All statistical analyses were conducted using SAS software version 9.4.”
“The Cam+nab-TP group received camrelizumab (200 mg on day 1), albumin-bound paclitaxel (125 mg/m² on days 1 and 8), and cisplatin (75 mg/m² on day 1).”
“PD-L1 expression levels at a central laboratory via immunohistochemistry (PD-L1 IHC 22C3 pharmDx kit, Dako).”
“All statistical analyses were conducted using SAS software version 9.4.”
Statistical tests are named (Cochran-Mantel-Haenszel test, Mantel-Haenszel method for differences/ORs). Assumptions are addressed through stratification and prespecified analysis. Exact p-values are reported (e.g., P < 0.0001, P = 0.0034). Effect sizes with confidence intervals are provided. Software is identified. Data presentation includes per-group n and confidence intervals. Mathematical plausibility checks are not applicable for large-N continuous outcomes.
“The pCR between Cam+nab-TP and TP groups as well as between Cam+TP and TP groups were compared by using stratified Cochran-Mantel-Haenszel test with the same stratification factor.”
“P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034”
“difference 23.5%, 95% confidence interval (CI), 15.1–32.0; odds ratio (OR), 8.11; 95% CI, 3.28–20.06”
“The pCR between Cam+nab-TP and TP groups as well as between Cam+TP and TP groups were compared by using stratified Cochran-Mantel-Haenszel test”
“P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034”
“difference 23.5%, 95% confidence interval (CI), 15.1–32.0; odds ratio (OR), 8.11; 95% CI, 3.28–20.06”
The data availability statement provides a concrete route: individual deidentified participant data can be requested 24 months after study completion via proposal to the corresponding author, with review and data access agreement. This is a managed-access mechanism, which is adequate for patient-level data. Repository deposit and accession numbers are not applicable for identifiable patient data. Code sharing is not applicable as no custom code was used.
“Due to intellectual property and confidentiality obligations, individual deidentified participant data that underlie the results reported in this article can be requested 24 months after study completion. Qualified researchers must submit a proposal to the corresponding author at liyin@cicams.ac.cn, outlining the reasons for requesting the data.”
“No custom code was used for data analysis in this study.”
“individual deidentified participant data that underlie the results reported in this article can be requested 24 months after study completion. Qualified researchers must submit a proposal to the corresponding author at liyin@cicams.ac.cn”
“The study protocol and statistical analysis plan are available alongside the published article.”
“No custom code was used for data analysis in this study.”
Methods are comprehensive and replicable. The trial is registered (ChiCTR2000040034). A reporting guideline (CONSORT) is not explicitly mentioned, but the paper includes a CONSORT diagram. All prespecified outcomes are reported (pCR and EFS, with EFS noted as immature). Limitations are thoroughly discussed. Conclusions are proportional to the evidence. Funding and competing interests are disclosed.
“Chinese Clinical Trial Registry identifier: ChiCTR2000040034”
“This study has several limitations. First, this study did not directly compare the two neoadjuvant chemotherapy regimens combined with camrelizumab that were tested.”
“Chinese Clinical Trial Registry identifier: ChiCTR2000040034”
“This study has several limitations. First, this study did not directly compare the two neoadjuvant chemotherapy regimens combined with camrelizumab that were tested.”
Registered (2 IDs: ClinicalTrials.gov, Chinese Clinical Trial Registry). Reporting guideline cited: CONSORT.
Broken references and links
1 finding · worst lowReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
- References not resolvable to a published paperRecomputed
Checked 51 references by DOI: 50 verified — 1 DOI unresolved.
- UNRESOLVED10.3760/cma.j.cn112137-20230604-00933Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition)Cited DOI does not resolve to any Crossref record.
2 data/code links checked; 2 live.
- datahttps://www.chictr.org.cn/showproj.html?proj=64180LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT04848753LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
5 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 5 minor suggestions below.
5 copyedit issues flagged: mostly clarity, grammar, consistency.
- MINORconsistencyAbstract“Cam+nab-TP versus TP: difference 23.5%, 95% confidence interval (CI) 15.1–32.0, P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034”→ Ensure consistent use of '95% CI' vs '95% confidence interval' throughout.Minor formatting inconsistency.
- MINORclarityMethods, Study design and patients“Thoracic esophageal cancer confirmed by computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), clinically staged as T1b-3N1-3M0 or T3N0M0 (https://www.uniprot.org/uniprot/T3N0M0)”→ Remove the erroneous URL link to UniProt; it is not relevant.Erroneous hyperlink.
- MINORgrammarDiscussion“The impact of pCR varies across different neoadjuvant regimens.”→ Consider rephrasing for clarity: 'The impact of pCR varies among neoadjuvant regimens.'Minor grammatical improvement.
- MINORclarityMethods, Study design and patients“Thoracic esophageal cancer confirmed by computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), clinically staged as T1b-3N1-3M0 or T3N0M0 (https://www.uniprot.org/uniprot/T3N0M0)”→ Remove the erroneous URL link to Uniprot for T3N0M0.The URL is irrelevant and likely a formatting error.
- MINORgrammarDiscussion“The impact of pCR varies across different neoadjuvant regimens.”→ Consider rephrasing to 'The impact of pCR varies among different neoadjuvant regimens.'Minor grammatical improvement.
The published paper is robust and methodologically sound. An informed reader should note the minor gaps (no explicit CONSORT or Declaration of Helsinki statement) and the one reference not found in the registry, but these do not undermine the core findings. No erratum or correction is warranted based on this audit.
- 1.HIGHreportingAdd an explicit statement of adherence to CONSORT reporting guidelines in the Methods or a dedicated Reporting Summary section.Both reviewers noted that a reporting guideline is not explicitly mentioned, which is a standard expectation for a phase 3 trial.
- 2.HIGHethicsAdd a statement of regulatory compliance (e.g., Declaration of Helsinki) in the Methods section.Both reviewers flagged that regulatory compliance is not explicitly stated, which is a minor but common reporting gap.
- 3.HIGHreportingVerify the reference 'Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition)' (DOI: 10.3760/cma.j.cn112137-20230604-00933) that was not found in the registry; correct or replace it if necessary.A reference not found in any registry may be fabricated or have an incorrect DOI; this is a potential integrity concern.
- 4.MEDIUMcopyeditRemove the erroneous URL link to UniProt (https://www.uniprot.org/uniprot/T3N0M0) in the Methods, Study design and patients section.The URL is irrelevant and likely a formatting error; it could confuse readers.
- 5.MEDIUMcopyeditStandardize the formatting of '95% CI' vs '95% confidence interval' throughout the manuscript (e.g., in the Abstract).Minor formatting inconsistency that can be easily harmonized.
- 6.MEDIUMcopyeditRephrase 'The impact of pCR varies across different neoadjuvant regimens' to 'The impact of pCR varies among different neoadjuvant regimens' in the Discussion.Minor grammatical improvement for clarity.
- 7.MEDIUMreportingClarify the manufacturer/source of camrelizumab in the Methods (e.g., Jiangsu Hengrui Pharmaceuticals).One reviewer noted that the source of the investigational product is not explicitly stated in the text, though it is implied by the sponsor.
- 8.MEDIUMreportingProvide the specific version of the PD-L1 IHC 22C3 pharmDx kit and any validation data in the Methods.One reviewer suggested improving key_resources reporting by including version and validation details.
- 9.MEDIUMreportingAdd a statement on the handling of missing data for PD-L1 status (e.g., imputation or sensitivity analysis) in the Statistical analysis section.One reviewer noted that missing data handling for PD-L1 is not addressed, which could affect subgroup analyses.
- 10.LOWreportingConsider providing a direct comparison between Cam+nab-TP and Cam+TP groups as a prespecified exploratory analysis to address the limitation noted in the Discussion.The authors themselves note this as a limitation; a prespecified exploratory analysis would strengthen the paper.
- 11.LOWreportingIn the Discussion, explicitly acknowledge that the pCR endpoint is a surrogate and that EFS/OS are needed to confirm clinical benefit.One reviewer suggested making this point more prominent to temper conclusions.
- 12.LOWdata codeConsider adding a data-sharing statement that includes an expected date for data availability (e.g., '24 months after study completion, expected by [date]').One reviewer noted that the timeline is vague without a specific date.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.